検索
Chemomab Therapeutics Ltd
CMMBウォッチリストに追加
2.600USD
-0.090-3.35%
終値 09-10 16:00（ET）
75.64M時価総額
14.98直近12ヶ月PER
時間外取引 (ET)0.000USD0.000
時間外取引 (ET)詳細情報 Chemomab Therapeutics Ltd 企業名
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd プロフィール
企業コードCMMB
会社名Chemomab Therapeutics Ltd
上場日Aug 14, 2012
最高経営責任者「CEO」Mor (Adi)
従業員数16
証券種類Depository Receipt
決算期末Aug 14
本社所在地Kiryat Atidim, Building 7
都市TEL AVIV-YAFO
証券取引所NASDAQ OMX - NASDAQ BASIC
国Israel
郵便番号6158002
電話番号972773310156
ウェブサイトhttps://www.chemomab.com/
企業コードCMMB
上場日Aug 14, 2012
最高経営責任者「CEO」Mor (Adi)
Chemomab Therapeutics Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
3.67K
--
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
3.67K
--
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
よくある質問
Chemomab Therapeutics Ltdの上位5名の株主は誰ですか？
Chemomab Therapeutics Ltdの上位5名の株主は以下のとおりです。Ms. Sigal Fattal, CPA
Chemomab Therapeutics Ltd（CMMB）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Chemomab Therapeutics Ltdの株式を保有している機関は33社あり、保有株式の総市場価値は約402.96Kで、全体の5.60%を占めています。2025Q4と比較して、機関の持ち株は-450971.00増加しています。